
    
      This is a phase I,single center, randomized, double-blind，single-dose and parallel group
      clinical trial . The primary objective is to assess the pharmacokinetic similarity of of
      QL1203 or Vectibix® in healthy male volunteers. The secondary objective are to assess the
      Clinical safety and immunogenicity similarity of QL1203 or Vectibix® in healthy male
      volunteers".
    
  